Drugs / 68Ga-C1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06519760 | Jul 2024 → Jun 2026 overdue | clear cell renal carcinoma | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-C1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06519760 ↗ |
| Modality | Small molecule | “CAIX specific small molecule probe 68Ga-C1” NCT06519760 ↗ |
| Route | Intravenous | “68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg” NCT06519760 ↗ |